Opinion|Videos|September 17, 2025
SALT Scoring for Alopecia Areata
Key Takeaways
- Alopecia areata is a chronic autoimmune disorder causing non-scarring hair loss due to immune system attacks on hair follicles.
- Breakdown of immune privilege in hair follicles leads to infiltration by cytotoxic T cells, particularly CD8+ T cells.
Panelists discuss how the Bayesian network meta-analysis showed which Janus kinase (JAK) inhibitors were most effective in reducing Severity of Alopecia Tool (SALT) scores in alopecia areata (AA), highlighting which therapies achieved 50% and 75% improvement, and whether SALT scores are an effective measure of treatment success.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Ungar: The Severity of Alopecia Tool (SALT) is a validated tool utilized to assess the clinical severity of alopecia with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss). In the Bayesian network
meta-analysis, which JAK inhibitor(s) demonstrated the best relative effect in reducing SALT scores pre and post intervention?- Which JAK inhibitor(s) demonstrated patients achieving 50% improvement?
- Which JAK inhibitor(s) demonstrated patients achieving 75% improvement?
- Do you believe this is an effective way to evaluate the effectiveness of an AA intervention?
Advertisement
Related to this article
At IDWeek 2026, IDSA and HIVMA leaders and clinician advocates outline how stories, relationships, and bipartisan outreach shape ID and HIV policy.
Insulin icodec-abae becomes the first once-weekly basal insulin cleared for children 10 years and older with type 2 diabetes.
At IDWeek 2026, Atul Gawande, MD, MPH, said USAID cuts are costing lives but that the field is "not back at square one."
More treatment choices does not always mean better patient outcomes, with care access remaining challenging in Florida.
About 9% of adults hospitalized with RSV died in the hospital or within 30 days of discharge, according to preliminary data presented at IDWeek 2026.
A systematic review found vitamin D did not consistently reduce MS relapse rates, though some studies reported lower MRI lesion activity.
Oncologists weighted how to choose, manage, and deliver new therapeutics beyond major academic centers.
Hiddo Heerspink, PhD, discusses finerenone data in type 1 diabetes, FSGS and IgA nephropathy, and open questions on sequencing CKD therapies.
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
Real-World AMKD Data Highlight Quick Progression, Unmet Needs
3
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
4
Former USAID Health Chief Says Aid Cuts Are Costing Children's Lives
5